Genprex(US:GNPX) Prnewswire·2026-02-23 13:00Core Insights - Genprex has strengthened its intellectual property portfolio by securing patents in Japan and the EU for Reqorsa® Gene Therapy in combination with immunotherapies to treat cancer [1] Intellectual Property Developments - The Japanese Patent Office has granted a patent for the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies for cancer treatment [1] - The European Patent Office has also issued a Decision to Grant for a patent related to the combination of Reqorsa and PD-1 antibodies for cancer treatment [1] - Genprex holds exclusive licenses to these patents, enhancing its protection for various therapeutic combinations, including those in the Acclaim-3 clinical trial [1] Clinical Trial Information - Acclaim-3 is a Phase 1/2 clinical trial evaluating Reqorsa in combination with Genentech's Tecentriq® for patients with extensive stage small cell lung cancer (ES-SCLC) [1] - The trial aims to determine the 18-week progression-free survival rate from the start of maintenance therapy with Reqorsa and Tecentriq [1] - The Phase 2 expansion study is expected to enroll approximately 50 patients, with an interim analysis planned after the 25th patient reaches 18 weeks of follow-up [1] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes [1] - The company utilizes a systemic, non-viral Oncoprex® Delivery System to administer disease-fighting genes [1] - Genprex's lead product candidate, Reqorsa® Gene Therapy, is being evaluated in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [1]